Investing.com - Concert Pharm reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Concert Pharm announced earnings per share of $-0.580 on revenue of $8K. Analysts polled by Investing.com EPS of $-0.592 on revenue of $165K.
Concert Pharm 's are down 28% and is trading at $4.940 , still down 32.97% from its 52 week high of $7.37 set on Thursday, August 11, 2022.
Concert Pharm shares lost 11.31% to trade at $4.940 in intra-day trade the report.
Concert Pharm follows other major Healthcare sector earnings this month
Concert Pharm's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar